These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Diplopia and fluoroquinolones. Fraunfelder FW; Fraunfelder FT Ophthalmology; 2009 Sep; 116(9):1814-7. PubMed ID: 19643481 [TBL] [Abstract][Full Text] [Related]
3. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use. Fraunfelder FW; Richards AB Ophthalmology; 2008 Dec; 115(12):2282-5. PubMed ID: 18930555 [TBL] [Abstract][Full Text] [Related]
4. Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports. Fraunfelder FW; Suhler EB; Fraunfelder FT Cutan Ocul Toxicol; 2010 Mar; 29(1):26-9. PubMed ID: 19947819 [TBL] [Abstract][Full Text] [Related]
5. Uveitis risk following oral fluoroquinolone therapy: a nested case-control Study. Forooghian F; Maberley D; Albiani DA; Kirker AW; Merkur AB; Etminan M Ocul Immunol Inflamm; 2013 Oct; 21(5):390-3. PubMed ID: 23876164 [TBL] [Abstract][Full Text] [Related]
6. Oral Fluoroquinolones and the Risk of Uveitis. Sandhu HS; Brucker AJ; Ma L; VanderBeek BL JAMA Ophthalmol; 2016 Jan; 134(1):38-43. PubMed ID: 26512796 [TBL] [Abstract][Full Text] [Related]
8. The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated diarrhea. Novell MJ; Morreale CA Ann Pharmacother; 2010 May; 44(5):826-31. PubMed ID: 20354161 [TBL] [Abstract][Full Text] [Related]
10. Ocular side effects from herbal medicines and nutritional supplements. Fraunfelder FW Am J Ophthalmol; 2004 Oct; 138(4):639-47. PubMed ID: 15488795 [TBL] [Abstract][Full Text] [Related]
11. Systemic Fluoroquinolone Use and Risk of Uveitis or Retinal Detachment. Brown JP; Wing K; Evans SJ; Leyrat C; Mansfield KE; Smeeth L; Wong AYS; Yorston D; Galwey NW; Douglas IJ JAMA Ophthalmol; 2024 Jul; 142(7):636-645. PubMed ID: 38814618 [TBL] [Abstract][Full Text] [Related]
12. Possible gatifloxacin-induced seizure. Quigley CA; Lederman JR Ann Pharmacother; 2004 Feb; 38(2):235-7. PubMed ID: 14742757 [TBL] [Abstract][Full Text] [Related]
13. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. Seeger JD; West WA; Fife D; Noel GJ; Johnson LN; Walker AM Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):784-92. PubMed ID: 16456878 [TBL] [Abstract][Full Text] [Related]
14. National trends in emergency department antibiotic prescribing for elders with urinary tract infection, 1996-2005. Caterino JM; Weed SG; Espinola JA; Camargo CA Acad Emerg Med; 2009 Jun; 16(6):500-7. PubMed ID: 19245373 [TBL] [Abstract][Full Text] [Related]
15. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Iannini PB Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736 [TBL] [Abstract][Full Text] [Related]
16. [Quinolone resistance in Gram negative rods in Iceland and association with antibiotic use]. Jónsdóttir K; Kristinsson KG Laeknabladid; 2008 Apr; 94(4):279-85. PubMed ID: 18460726 [TBL] [Abstract][Full Text] [Related]
17. Bilateral acute iris transillumination following systemic moxifloxacin for respiratory illness: report of two cases and review of the literature. Morshedi RG; Bettis DI; Moshirfar M; Vitale AT Ocul Immunol Inflamm; 2012 Aug; 20(4):266-72. PubMed ID: 22694259 [TBL] [Abstract][Full Text] [Related]
18. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. van der Linden PD; van Puijenbroek EP; Feenstra J; Veld BA; Sturkenboom MC; Herings RM; Leufkens HG; Stricker BH Arthritis Rheum; 2001 Jun; 45(3):235-9. PubMed ID: 11409663 [TBL] [Abstract][Full Text] [Related]
19. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Fuller JD; Low DE Clin Infect Dis; 2005 Jul; 41(1):118-21. PubMed ID: 15937772 [TBL] [Abstract][Full Text] [Related]
20. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Jones SC; Sorbello A; Boucher RM Drug Saf; 2011 Oct; 34(10):839-47. PubMed ID: 21879778 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]